ABSTRACT
In the pediatric patient, the presence of gammopathies can be seen in various disease processes. This study helps to expand our understanding of the clinical disorders associated with pediatric gammopathies. In the clinical laboratory, a monoclonal or oligoclonal gammopathy is often first recognized by an electrophoretically restricted band or "spike" usually seen in the b to g region of the serum protein electrophoresis (SPEP) test. It is confirmed by demonstrating its antigenic specificity for one immunoglobulin (Ig) class and one light chain type with serum immunofixation electrophoresis (SIFE).
Monoclonal proteins are infrequently observed in young patients. Moreover, malignant plasma cell disorders associated with monoclonal proteins are extremely rare in young patients. 1 Specifically, fewer than 1% of all cases of malignant plasma cell disorders are reported in patients younger Upon completion of this activity you will be able to:
• list the categories of diseases associated with monoclonal and oligoclonal gammopathies in children.
• characterize the monoclonal and oligoclonal proteins in children with gammopathies.
• describe the similarities and differences in diseases associated with gammopathies between children and adults.
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than 30 years. [2] [3] [4] In the pediatric age group, multiple myeloma has been reported in only 12 instances since 1973. 1 In this study, we performed an electronic chart review from 2005 until 2011 and identified all pediatric patients who were found to have a gammopathy as defined by an abnormal SIFE result. We documented 83 patients who met our criteria and described and categorized the primary medical diagnoses of these patients.
Materials and Methods

Patient Population
This retrospective study evaluated the medical history of all patients aged 0 to 21 years who received an SIFE evaluation in the immunology laboratory at The Johns Hopkins Hospital (Baltimore, MD). All individuals who were diagnosed with SIFE as having a monoclonal, biclonal, or oligoclonal gammopathy between January 1, 2005, and September 9, 2011, were included in this study. The electronic medical record was used to identify the patient's age at the time of diagnosis, sex, and race, and the medical history was evaluated. This study was approved by The Johns Hopkins Medical Institutions' institutional review board.
Laboratory Methods
Monoclonal and oligoclonal proteins were evaluated with SPEP, SIFE, and nephelometric quantitation of Igs. SPEP was performed on agarose gels in alkaline buffer (Sebia Laboratories, Norcross, GA). The serum IgG, IgA, and IgM concentrations were quantified using nephelometry on the IMMAGE instrument (Beckman-Coulter, Fullerton, CA), and SIFE was performed on the Paragon system (Beckman-Coulter). All assays were performed according to the manufacturers' procedures.
Summary statistics and statistical analyses were performed using Vassarstats (http://faculty.vassar.edu/lowry/VassarStats. html) and Microsoft Excel (Redmond, WA) when needed. Confidence intervals for binary outcomes were calculated using exact methods. P less than .05 was considered statistically significant. Because of the very small number of patients who underwent SPEP or SIFE multiple times, only the first result from all patients was subsequently used in the analysis.
Results
A total of 695 SIFE tests were performed on patients aged 0 to 21 years during the study period. Of these, 95 SIFE (14%) tests identified a gammopathy in 83 pediatric patients, and 74 SIFE (11%) tests demonstrated a monoclonal gammopathy in 63 pediatric patients.
Demographics and Monoclonal Protein Characterization
The 95 positive results on SIFE were obtained from 83 pediatric patients. Most of our study population underwent only one or two SIFE tests during the study period (range, 1-7). Of the 83 patients, 42 were female (51%) and 41 were male (49%). The average age of our patient population was 10.9 years, with a standard deviation of 6.9. ❚Figure 1❚ shows the age distribution of patients with a documented gammopathy in our patient population. The histogram reveals that gammopathies generally occur throughout childhood and are not more common among older children (P > .05). A specific overlapping cluster of very young pediatric patients was noted for those with congenital diseases. This finding was mainly seen in the patients with ataxia-telangiectasia, which will be described in greater detail later ❚Table 1❚. Most of the patients in our cohort were white, with 62% of monoclonal proteins and 48% of oligoclonal proteins occurring in this group. African American patients made up the second most common race (21% of monoclonal proteins, 29% of oligoclonal gammopathy), followed by Asian (5% of monoclonal and 10% of oligoclonal gammopathy) and Hispanic patients (5% of monoclonal and 5% of oligoclonal gammopathy). Using only the first abnormal SIFE result from each of the 63 patients with a monoclonal gammopathy, it was noted that IgG was the most common monoclonal heavy chain, present in 76% of all the monoclonal gammopathies identified. IgM was the second most common, accounting for 19% of the monoclonal gammopathies, and IgA was least common (3%). ❚Table 2❚ shows the distribution of the monoclonal proteins identified in this study. Although IgG κ monoclonal gammopathies were more common than IgG l, the reverse was true with IgM monoclonal gammopathies.
Diagnoses
The diagnoses associated with the observed gammopathies were numerous, but as shown in ❚Table 3❚, they are divided into six broad categories: congenital diseases, autoimmune diseases, infectious diseases, hematologic conditions, solid organ malignancies, and other. None of the 83 patients was diagnosed with a malignant gammopathy (multiple myeloma or Waldenström macroglobulinemia) or amyloidosis. Primary congenital diagnoses specifically associated with (Table 3 ). Table 1 demonstrates that age was not significantly associated with any of the diagnoses (P > .05). ❚Table 4❚ describes the relationship between the gammopathy type and the primary diagnosis in the patient's medical record. As demonstrated by the table, congenital disease was by far the most common cause of monoclonal and oligoclonal gammopathies in the pediatric age group, followed by hematologic diseases, autoimmune diseases, infectious diseases, solid malignancies, and other/unknown conditions. Although the numbers evaluated were small, the likelihood was stronger that a monoclonal protein would be identified in those with congenital, autoimmune, infectious, and hematologic disease. In contrast, monoclonal and oligoclonal proteins were seen evenly in those with solid organ malignancies and solid organ transplantations. ❚Table 5❚ describes the relationship between bone marrow transplantation and monoclonal gammopathies in this population. In total, 15 patients had received a bone marrow transplant, of whom two were treated for congenital disease, nine were treated for hematologic illness, and four were treated for a solid organ malignancy. Of these, eight (53%) had an SIFE test before transplantation. None of the patients with congenital disease, five (56%) of those with hematologic disease, and three (75%) with organ malignancy had a monoclonal protein before bone marrow transplantation.
Discussion
Gammopathies in children are uncommon. At our institution, we found that only 14% of all SIFE tests ordered for patients aged 0 to 21 years identified a gammopathy, and 74 SIFE (11%) tests representing 63 patients were defined as demonstrating a monoclonal gammopathy. Pediatric patients demonstrating a gammopathy had a diverse range of clinical diagnoses, with many involving congenital immunodeficiencies, autoimmune diseases, malignancies, or hematologic disorders. To our knowledge, this study represents the largest report of its kind to specifically evaluate a cohort of pediatric patients with a documented monoclonal or oligoclonal gammopathy. The last large population-based study to evaluate gammopathies in children was reported in 1989. Specifically, Gerritsen et al 5 over a 10-year period evaluated the serum samples of 4,000 pediatric patients. Retrospective analysis revealed the presence of a gammopathy in the serum samples of 155 children (4% of their total population). Similar to our own findings, gammopathies were more frequently found in patients suffering from primary and secondary immunodeficiency diseases, hematologic malignancies, autoimmune diseases, and severe aplastic anemia. Interestingly, the gammopathies in the serum samples of 79 patients evaluated with SIFE revealed a marked absence of IgA gammopathies and a predominance of the l light-chain isotype. 5 These findings were not replicated in our study.
Most studies investigating gammopathy in children have been limited to specific disease entities and case reports. Gammopathies have been previously reported in children with HIV-AIDS 6 ; polyneuropathy, organomegaly, endocrinopathy or edema, M-protein, and skin abnormalities (POEMS) syndrome 7, 8 ; SCID, both before and after bone marrow transplantation 9,10 ; Wiskott-Aldrich and Nezelof syndromes; and ataxia-telangiectasia. 5, 11 In this study, we identified a large group of patients with ataxia-telangiectasia (22%) with either a monoclonal or oligoclonal gammopathy. Ataxia-telangiectasia is an autosomal recessive disorder presenting in childhood and is characterized by cerebellar ataxia, oculocutaneous telangiectasias, and B-and T-cell immunodeficiencies. 11 Our study supports the well-documented, albeit rare, characteristic of gammopathies in this patient population. 5, [11] [12] [13] Specifically, investigators at our own institution previously reported that 8% of the 86 patients with ataxia-telangiectasia had either a monoclonal or oligoclonal gammopathy. 11 Studies in adults affirm that patients with chronic antigenic stimulation, such as those with autoimmune diseases or infection (ie, HIV), have a higher risk for a monoclonal gammopathy than the general population. [14] [15] [16] [17] [18] [19] In our study, three pediatric HIV cases were identified that were associated with a gammopathy. Also, the incidence of monoclonal gammopathy is higher in adults with suppressed immune systems, such as those who have undergone organ transplantation who can develop posttransplant lymphoproliferative disease (PTLD). 20 Our study identified one PTLD case in association with a gammopathy. Other documented associations for the presence of monoclonal gammopathies in adults includes environmental exposures, such as exposure to pesticide, asbestos, aromatic hydrocarbons, fertilizers, mineral oils, petroleum, paint, radiation or tobacco, and family history. [21] [22] [23] [24] [25] [26] [27] We could not determine the presence of these associations in our cohort.
Similar patterns of disease groups were also noted in a large hospital population study, which revealed a monoclonal protein in 10% of all patients older than 40 years. 28 That study found an overall distribution analogous to that seen in our younger pediatric population, with 67% with IgG, 18% with IgM, and 15% with an IgA gammopathy. In their review of patient history, they also noted many similar underlying conditions associated with the monoclonal protein including autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis, Crohn disease, etc), solid tumors, hematologic diseases (Castleman disease, mycosis fungoides, hairy cell leukemia, Hodgkin disease, marginal zone lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphoid leukemia), renal diseases, liver cirrhosis, bacterial sepsis, immunemediated polyneuropathy, and myelodysplasia. A main difference between our study and studies conducted in the adult population was that 50% of the adult population have been found to have a malignant monoclonal gammopathy, including multiple myeloma, plasmacytoma, primary amyloidosis, and Waldenström macroglobulinemia. 28 Nevertheless, our patients are distinct from the adult cases reported by Simon et al 28 in that none of the aforementioned malignant monoclonal gammopathies (multiple myeloma, plasmacytoma, primary amyloidosis, and Waldenström macroglobulinemia) were identified in our young cohort.
Gerritsen et al 5 reported that studies in children suggest that without underlying immune deficiencies, the gammopathies are usually transient, lasting less than 1 year, and do not lead to an increased risk of malignancy. However, Bruce and Blaese 29 commented that in children with underlying primary immune deficiencies, although the risk of malignancy is increased, this risk is not due to the gammopathy. Nevertheless, our study cannot address the relationship between gammopathies and malignancies.
Our retrospective study has a number of limitations. First, this study identified patients based on positive SIFE results. Consequently, our study population is biased based on the specific tertiary pediatric referral clinics that request SPEP and SIFE at our hospital. As a result, we cannot say with certainty that the distribution of patients represented in this study can be generalized. For example, Gerritsen et al 5 found that only one patient with ataxia-telangiectasia had a gammopathy, whereas we found that ataxia-telangiectasia represented more than 20% of all abnormal SIFE findings. These data are skewed because our institution has a center for the study of ataxia-telangiectasia. Second, because this study was retrospective, we could not follow the patient's gammopathies over time, and therefore we could not determine whether these gammopathies were transient or altered because of transplantation or medical therapy. Although a very small number of our patient population had more than one abnormal SIFE result during our study period, we limited our analysis only to the first abnormal SIFE result for each patient because the additional SIFE results only added bias and falsely inflated the distribution of some of the monoclonal and oligoclonal proteins evaluated in our population.
Despite these limitations, we found that various autoimmune diseases, hematologic diseases, malignancies, transplantations, and immunodeficiencies are associated with the coexistence of monoclonal or oligoclonal gammopathies in children. With the exception of malignant gammopathies, such as Waldenström macroglobulinemia and multiple myeloma, these findings are similar to those seen in adults. Moreover, as seen in adults, children develop gammopathies that are predominantly IgG, with IgM representing 19% of cases. This study demonstrates in a large cohort at a single institution the diversity of disease processes that are associated with gammopathies in pediatric patients. Long-term studies are needed to clarify the significance of these gammopathies in this young population as they age.
